 Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations 